

Remarks


The sequence listing has been amended to comply with the U.S. Patent and Trademark Office requirements in accordance with the disclosure as set forth in 37 C.F.R. §1.821 – 1.825. Applicants accordingly submit a Second Substitute Sequence Listing in written and computer readable forms that corrects the defects noted in the raw sequence listing accompanying the Notice to Comply. No new matter has been added to the substitute Sequence Listing.

In view of the foregoing remarks, Applicants believe that this application is now in condition for allowance, and an early notice to that effect is urged. The Examiner is invited to call the undersigned at the phone number provided below if any further action by Applicants would expedite the examination of this application.

Finally, if there are any fees due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 08-3425. If a fee is required for an additional extension of time under 37 C.F.R. § 1.136, such an extension is requested and the appropriate fee should also be charged to our Deposit Account.

Dated: December 18, 2003

Respectfully submitted,

By 
Melissa J. Pytel

Registration No.: 41,512
HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue
Rockville, Maryland 20850
(301) 610-5764

MJH/MJP/KM/lcc